Nature Communications (Feb 2017)
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
- Adrian Vallejo,
- Naiara Perurena,
- Elisabet Guruceaga,
- Pawel K. Mazur,
- Susana Martinez-Canarias,
- Carolina Zandueta,
- Karmele Valencia,
- Andrea Arricibita,
- Dana Gwinn,
- Leanne C. Sayles,
- Chen-Hua Chuang,
- Laura Guembe,
- Peter Bailey,
- David K. Chang,
- Andrew Biankin,
- Mariano Ponz-Sarvise,
- Jesper B. Andersen,
- Purvesh Khatri,
- Aline Bozec,
- E. Alejandro Sweet-Cordero,
- Julien Sage,
- Fernando Lecanda,
- Silve Vicent
Affiliations
- Adrian Vallejo
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Naiara Perurena
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Elisabet Guruceaga
- University of Navarra, Center for Applied Medical Research, Proteomics, Genomics and Bioinformatics Core Facility
- Pawel K. Mazur
- Department of Genetics, Stanford University School of Medicine
- Susana Martinez-Canarias
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Carolina Zandueta
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Karmele Valencia
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Andrea Arricibita
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Dana Gwinn
- Department of Pediatrics, Stanford University School of Medicine
- Leanne C. Sayles
- Department of Pediatrics, Stanford University School of Medicine
- Chen-Hua Chuang
- Department of Pediatrics, Stanford University School of Medicine
- Laura Guembe
- University of Navarra, Center for Applied Medical Research, Morphology Unit
- Peter Bailey
- Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate
- David K. Chang
- Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate
- Andrew Biankin
- Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate
- Mariano Ponz-Sarvise
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Jesper B. Andersen
- Biotech Research and Innovation Center, University of Copenhagen
- Purvesh Khatri
- Stanford Institute for Immunity, Transplantation and Infection
- Aline Bozec
- Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg
- E. Alejandro Sweet-Cordero
- Department of Pediatrics, Stanford University School of Medicine
- Julien Sage
- Department of Genetics, Stanford University School of Medicine
- Fernando Lecanda
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- Silve Vicent
- University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Biomarkers
- DOI
- https://doi.org/10.1038/ncomms14294
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
KRAS-driven cancers remain refractory to current clinical therapies. In this study, the authors show that lung and pancreatic cancers expressing oncogenic KRAS can be targeted by genetic inhibition of FOSL1, which involves downregulation of genes of the mitotic machinery.
